Skip to main content

ADVERTISEMENT

Mike Cowley, MD

Commentary
08/01/2008
Jim Zidar: We have chosen magnetic resonance imaging as our primary imaging tool at Duke University. A new cardiac magnetic resonance imaging research laboratory is being installed at Duke, with an adjacent clinical laboratory. In our view,...
Jim Zidar: We have chosen magnetic resonance imaging as our primary imaging tool at Duke University. A new cardiac magnetic resonance imaging research laboratory is being installed at Duke, with an adjacent clinical laboratory. In our view,...
Jim Zidar: We have chosen...
08/01/2008
Journal of Invasive Cardiology
Commentary
08/01/2008
(IAGS Proceedings - Part II of II) Nick Hopkins: The preliminary reports on intracranial angioplasty and stenting showed very high morbidity and mortality rates associated with the procedure — particularly in symptomatic patients. As Dr....
(IAGS Proceedings - Part II of II) Nick Hopkins: The preliminary reports on intracranial angioplasty and stenting showed very high morbidity and mortality rates associated with the procedure — particularly in symptomatic patients. As Dr....
(IAGS Proceedings - Part II of...
08/01/2008
Journal of Invasive Cardiology
IAGS (International Andreas Gruentzig Society) Proceedings
08/01/2008
Mike Cowley: Let’s begin with discussing case selection. Which patients should receive drug-eluting stents (DES)? Should they only receive one stent? Should we reserve DES for a select patient population? What should the approach be for...
Mike Cowley: Let’s begin with discussing case selection. Which patients should receive drug-eluting stents (DES)? Should they only receive one stent? Should we reserve DES for a select patient population? What should the approach be for...
Mike Cowley: Let’s begin with...
08/01/2008
Journal of Invasive Cardiology
IAGS (International Andreas Gruentzig Society) Proceedings
08/01/2008
Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly &...
08/01/2008
Journal of Invasive Cardiology